NCT05085587

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Bioequivalence Study With Pharmacokinetic Endpoints Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Respirent Pharmaceuticals Co Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder

Detailed description

A bioequivalence study of a single dose of the fixed-dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder administered from Fluticasone propionate 250 mcg and Salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals (test-Τ) as 2 inhalations and ADVAIR DISKUS® 250/50 mcg inhalation powder/GSK (reference-R) in healthy volunteers under fasting conditions. The study will be one-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory blinded

Conditions

• Bioequivalence
• Asthma

Interventions

Type	Name	Description
DRUG	Test	2 inhalations of Test and Reference product in each study period
DRUG	Reference	2 inhalations of Test and Reference product in each study period

Timeline

• Start date: 2021-10-01
• Primary completion: 2021-10-25
• Completion: 2021-12-30
• First posted: 2021-10-20
• Last updated: 2021-10-20

Locations

1 site across 1 country: Greece

Regulatory

• FDA-regulated drug study